Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)‘s stock had its “positive” rating reissued by analysts at Guggenheim in a research note issued to investors on Tuesday. They currently have a $12.00 price objective on the stock. Guggenheim’s target price suggests a potential upside of 126.42% from the company’s previous close.
Separately, Chardan Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Aralez Pharmaceuticals in a report on Sunday, August 14th.
Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 5.30 on Tuesday. The company’s market capitalization is $345.78 million. The stock’s 50 day moving average price is $5.30 and its 200 day moving average price is $4.16. Aralez Pharmaceuticals has a 12 month low of $3.10 and a 12 month high of $8.59.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.08. Aralez Pharmaceuticals had a negative return on equity of 73.21% and a negative net margin of 224.35%. The firm earned $12.60 million during the quarter, compared to the consensus estimate of $9.70 million. The firm’s quarterly revenue was up 142.3% compared to the same quarter last year. Equities research analysts anticipate that Aralez Pharmaceuticals will post ($1.05) earnings per share for the current fiscal year.
In other Aralez Pharmaceuticals news, Director Robert Paul Harris sold 150,000 shares of the business’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $5.82, for a total transaction of $873,000.00. Following the completion of the sale, the director now owns 669,094 shares of the company’s stock, valued at $3,894,127.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.77% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. JW Asset Management LLC raised its stake in Aralez Pharmaceuticals by 49.1% in the second quarter. JW Asset Management LLC now owns 2,737,140 shares of the company’s stock valued at $9,033,000 after buying an additional 900,765 shares in the last quarter. Deerfield Management Co. bought a new stake in Aralez Pharmaceuticals during the first quarter valued at about $5,838,000. Janus Capital Management LLC raised its stake in Aralez Pharmaceuticals by 1.3% in the second quarter. Janus Capital Management LLC now owns 1,603,757 shares of the company’s stock valued at $5,292,000 after buying an additional 20,623 shares in the last quarter. Elk Creek Partners LLC raised its stake in Aralez Pharmaceuticals by 8.8% in the second quarter. Elk Creek Partners LLC now owns 1,514,918 shares of the company’s stock valued at $2,518,000 after buying an additional 122,172 shares in the last quarter. Finally, Tiger Legatus Capital Management LLC raised its stake in Aralez Pharmaceuticals by 17.6% in the second quarter. Tiger Legatus Capital Management LLC now owns 1,500,000 shares of the company’s stock valued at $4,950,000 after buying an additional 225,000 shares in the last quarter. 49.63% of the stock is owned by institutional investors and hedge funds.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.